SCHEMBL6316533

SCHEMBL6316533

NC(=O)c1c(-c2cccs2)noc1NC(=O)c1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY1 Q08828 2/20 0.54
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 2/20 0.47
THRB P10828 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA7 P43166 2/20 0.46
GABRD O14764 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRA4 P48169 1/20 0.44
RAB9A P51151 2/20 0.43
FLT3 P36888 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314638 0.89 ALDH1A1 (0.54) ADCY1MEN1KMT2AMAPTTDP1
SCHEMBL6315217 0.88 HTT (0.45) ADCY1MEN1KMT2APOLBMAPT
SCHEMBL6318622 0.87 MAPT (0.47) ADCY1MEN1KMT2APOLBMAPT
SCHEMBL6316047 0.87 GABRD (0.47) MEN1KMT2APOLBMAPTTDP1
SCHEMBL6316376 0.86 SMN1; SMN2 (0.50) ADCY1MAPTRAB9AFLT3ALDH1A1
SCHEMBL6318710 0.85 HDAC1 (0.43) ADCY1MEN1KMT2AMAPTTHRB
SCHEMBL6315171 0.85 ADCY1 (0.56) ADCY1MEN1KMT2APOLBMAPT
SCHEMBL6323548 0.85 MAPT (0.52) MEN1KMT2AMAPTTHRBALDH1A1
SCHEMBL6317259 0.84 MAPT (0.53) MEN1KMT2APOLBMAPTTHRB
SCHEMBL6317723 0.83 KMT2A (0.53) MEN1KMT2AMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ADCY1 2190/4885MEN1 2789/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.